Nucleic acid–based therapeutics in orphan neurological disorders: Recent developments
O Khorkova, J Hsiao, C Wahlestedt - Frontiers in molecular …, 2021 - frontiersin.org
The possibility of rational design and the resulting faster and more cost-efficient
development cycles of nucleic acid–based therapeutics (NBTs), such as antisense …
development cycles of nucleic acid–based therapeutics (NBTs), such as antisense …
Gene, stem cell, and future therapies for orphan diseases
MI Phillips - Clinical Pharmacology & Therapeutics, 2012 - Wiley Online Library
There are an estimated 7,000 “orphan diseases,” but treatments are currently available for
only about 5% of them. Recent progress in the advanced platforms of gene therapy, stem …
only about 5% of them. Recent progress in the advanced platforms of gene therapy, stem …
[HTML][HTML] Neurologic orphan diseases: Emerging innovations and role for genetic treatments
IP Kioutchoukova, DT Foster, RN Thakkar… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Orphan diseases are rare diseases that affect less than 200000 individuals within the United
States. Most orphan diseases are of neurologic and genetic origin. With the current …
States. Most orphan diseases are of neurologic and genetic origin. With the current …
Preparing n-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives
M Synofzik, WMC van Roon-Mom… - nucleic acid …, 2022 - liebertpub.com
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on “more …
approach for rare neurological diseases (RNDs). However, the current focus is on “more …
[HTML][HTML] Antisense drugs for rare and ultra-rare genetic neurological diseases
ME McCauley, CF Bennett - Neuron, 2023 - Elsevier
The regulatory approvals of nusinersen and tofersen, plus the large body of clinical and
preclinical data from other drugs, have significantly de-risked antisense technology for …
preclinical data from other drugs, have significantly de-risked antisense technology for …
Recent advances in RNA therapy and its carriers to treat the single-gene neurological disorders
MJ Lee, I Lee, K Wang - Biomedicines, 2022 - mdpi.com
The development of new sequencing technologies in the post-genomic era has accelerated
the identification of causative mutations of several single gene disorders. Advances in cell …
the identification of causative mutations of several single gene disorders. Advances in cell …
The potential of antisense as a CNS therapeutic
J Godfray, P Estibeiro - Expert Opinion on Therapeutic Targets, 2003 - Taylor & Francis
Antisense offers a precise and specific means of knocking down expression of a target gene,
and is a major focus of research in neuroscience and other areas. It has application as a tool …
and is a major focus of research in neuroscience and other areas. It has application as a tool …
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
The rising median age of our population and the age-dependent risk of neurodegeneration
translate to exponentially increasing numbers of afflicted individuals in the coming years …
translate to exponentially increasing numbers of afflicted individuals in the coming years …
Brain somatic mutations as RNA therapeutic targets in neurological disorders
S Lee, JH Lee - Annals of the New York Academy of Sciences, 2022 - Wiley Online Library
Research into the genetic etiology of a neurological disorder can provide directions for
genetic diagnosis and targeted therapy. In the past, germline mutations, which are …
genetic diagnosis and targeted therapy. In the past, germline mutations, which are …
Cerebral organoids and antisense oligonucleotide therapeutics: challenges and opportunities
The advent of stem cell-derived cerebral organoids has already advanced our
understanding of disease mechanisms in neurological diseases. Despite this, many remain …
understanding of disease mechanisms in neurological diseases. Despite this, many remain …